Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS6417206 B1
Publication typeGrant
Application numberUS 09/771,130
Publication dateJul 9, 2002
Filing dateJan 26, 2001
Priority dateJan 26, 2001
Fee statusPaid
Also published asCA2372538A1
Publication number09771130, 771130, US 6417206 B1, US 6417206B1, US-B1-6417206, US6417206 B1, US6417206B1
InventorsRonald Leflein, Alexander D. D'Addio
Original AssigneeMedpointe Healthcare Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Antitussive/antihist aminic/decongestant compositions
US 6417206 B1
Abstract
Tannate compositions are disclosed consisting essentially of carbetapentane tannate, pyrilamine tannate and phenylephrine tannate are effective when administered orally for the symptomatic relief of cough associated with respiratory tract conditions such as the common cold, bronchial asthma, acute and chronic bronchitis.
Images(3)
Previous page
Next page
Claims(14)
What is claimed:
1. A therapeutic composition for the symptomatic relief of cough associated with adverse respiratory tract conditions in warm-blooded animals in need of such treatment said composition comprising pharmaceutically effective amounts of active ingredients, wherein said active ingredients consist of carbetapentane tannate, pyrilamine tannate and phenylephrine tannate.
2. The therapeutic composition of claim 1 in tablet form.
3. The therapeutic composition of claim 2 wherein each tablet contains 50 to 75 mg of carbetapentane tannate, 30 to 50 mg of pyrilamine tannate and 5 to 15 mg of phenylephrine tannate.
4. The therapeutic composition of claim 2 wherein said tablet form contains about 60 mg of cabetapentane tannate, about 40 mg of pyrilamine tannate, and about 10 mg of phenylephrine tannate.
5. The therapeutic composition of claim 1 in suspension form.
6. The therapeutic composition of claim 5 wherein 5 ml. of the suspension contain 20 to 30 mg of carbetapentane tannate, 25 to 30 mg of pyrilamine tannate and 3 to 8 mg of phenylephrine tannate.
7. The therapeutic composition of claim 5 wherein said suspension form contains about 30 mg of cabetapentane tannate, about 30 mg of pyrilamine tannate, and about 5 mg of phenylephrine tannate, per 5 ml.
8. A method for symptomatically treating and relieving the distress of cough associated with adverse respiratory tract conditions in warm-blooded animals comprising orally administering to warm-blooded animals in need of such treatment of the composition of claim 1.
9. The method of claim 8 wherein said composition is in tablet form.
10. The method of claim 9 wherein each tablet contains 50 to 75 mg of carbetapentane tannate, 30 to 50 mg of pyrilamine tannate and 5 to 15 mg of phenylephrine tannate.
11. The method of claim 9 wherein said tablet form contains about 60 mg of cabetapentane tannate, about 40 mg of pyrilamine tannate, and about 10 mg of phenylephrine tannate.
12. The method of claim 8 wherein said composition is a suspension.
13. The method of claim 12 wherein 5 ml. of the suspension contain 20 to 30 mg of carbetapentane tannate, 25 to 30 mg of pyrilamine tannate and 3 to 8 mg of phenylephrine tannate.
14. The method of claim 12 wherein said suspension contains about 30 mg of cabetapentane tannate, about 30 mg of pyrilamine tannate, and about 5 mg of phenylephrine tannate, per 5 ml.
Description
FIELD OF INVENTION

The invention relates to novel antitussive/antihistiminic/decongestant tannate compositions. The compositions contain as essential ingredients carbetapentane tannate, pyrilamine tannate and phenylephrine tannate.

BACKGROUND OF INVENTION

A considerable number of tannic acids occur in nature. Chemically, these acids are described as polymers of different hydroxybenzoic acids. Generally, when the term tannic acid is employed, as in the present case, the acid referred to is gallotannic acid, the internal ester of gallic acid also frequently referred to as tannin.

Tannic Acid consists of an amorphous powder glistening scales or spongy masses varying in color from yellowish-white to light brown. Tannic acid is very soluble in water, glycerine or alcohol.

Tannic acids are usually obtained from glycosides which consist of several molecules of a tannic acid in combination with glucose.

Commercially available, tannic acid, also known as Tannin, has a complex non-uniform chemistry, usually contains from about 5% to about 10% by weight water, has a molecular weight of about 1700, and is typically produced from Turkish or Chinese nutgall.

Carbetapentane, known chemically as 2-[2-(diethylamino)ethoxy]ethyl 1-phenylcyclopentanecarboxylate is an antitussive compound that is described in U.S. Pat. No. 2,842,585 and is structurally related to caramiphen. Carbetapentane citrate has a melting point of 93 C. and occurs as a white powder freely soluble in water and slightly soluble in alcohol.

Carbetapentane has an atropine-like action that depresses the cough reflex by selective central nervous system depression.

Pyrilamine is one of the oldest and most enduring antihistaminic drugs, known chemically as N-[(4-methoxyphenyl)methyl]-N′,N′-dimethyl-N-2-pyridinyl-1,2-ethanediamine, its preparation is disclosed in U.S. Pat. No. 2,502,151 and is an oily liquid. Pyrilamine hydrochloride salt is very soluble in water and has a melting point of 143-143.5 C. whereas the maleate salt is slightly soluble in water, benzene and ether and has a melting point of 100-101 C.

Phenylephrine, known chemically as (−)-m-hydroxy-α-[(methylamino)-methyl] benzyl alcohol, is a synthetic, optically active sympathomimetic amine which has one hydroxyl group on the benzene ring. The hydroxyl group is placed in the position meta to the aliphatic side chain. The meta position affords optimal activity and phenylephrine (neo-synephrine) replaced an older preparation, synephrine, in which the hydroxyl was in the para position.

Phenylephrine hydrochloride is available in the form of the levorotatory isomer, a white, odorless, non-hygroscopic, crystalline compound possessing a bitter taste. Phenylephrine hydrochloride has a melting point of 140-145 C. and is freely soluble in water and alcohol.

Antitussive, antihistamine and decongestant compounds in the form of their free bases as well as their salts, e.g. hydrochloride, citrate, maleate, tannate, etc., are well known. Antitussives, antihistamines and decongestants in the form of their tannate salts are very desirable because such salts are generally stable and may be combined in such form without any untoward side effects.

Antitussives, antihistamines and decongestants in the form of their tannate salts are typically prepared by reacting the free base, e.g. carbetapentane, pyrilamine, phenylephrine, etc. with tannic acid in the presence of a volatile solvent, usually isopropanol. Typically, in the conventional isopropanol route, the antitussive, antihistaminic or decongestant free base and the tannic acid will be present in the isopropanol at a concentration of about 20% based on the weight of the reaction mixture. The reaction mixture is stirred for about one hour while maintaining the mixture at 60-70 C. The reaction mixture is cooled to room temperature and then filtered, washed with isopropanol and then vacuum dried. Alternative routes to the tannate salts are described in U.S. Pat. No. 5,599,846 and U.S. Pat. No. 5,663,415.

THE INVENTION

It has now been found that the novel combination of carbetapentane tannate, pyrilamine tannate and phenylephrine tannate produces a composition having antitussive, antihistaminic and sympathomimetic decongestant properties superior to the use of any one of the tannate compounds alone.

The compositions of the present invention may be prepared for oral administration in the form of powders, capsules, elixirs, syrups and the preferred forms of tablets or suspensions formulated so that ideally each tablet contains approximately 50 to 75 mg of carbetapentane tannate, preferably about 60 mg of carbetapentane tannate, approximately 30 to 50 mg pyrilamine tannate, preferably about 40 mg of pyrilamine tannate, and approximately 5 to 15 mg phenylephrine tannate, preferably about 10 mg phenylephrine tannate or that ideally each 5 mL (approximately 1 teaspoon) of suspension would contain approximately 20 to 30 mg carbetapentane tannate, preferably 30 mg of carbetapentane tannate, 25 to 30 mg pyrilamine tannate, preferably 30 mg of pyrilamine tannate, and 3 to 8 mg of phenylephrine tannate, preferably 5 mg of phenylephrine tannate.

Tablets containing the unique tannate combination of the present invention are prepared in a conventional manner by the addition of suitable pharmaceutical carriers including fillers, diluents, colorants, lubricants and the like as well as conventional and well known binding and disintegrating agents. A typical tablet composition of the present invention containing starch, dibasic calcium phosphate, colorants, magnesium stearate, methylcellulose, polygalacturoic acid, povidone and talc as described in Example 1 which follows is prepared by well known conventional tabletting techniques such as those disclosed in U.S. Pat. Nos. 3,018,221; 2,798,024 and 2,757,124.

EXAMPLE 1 Carbetapentane Tannate, Pyrilamine Tannate and Phenylephrine Tannate Tablets

Ingredient Milligrams per Tablet
Carbetapentane Tannate 60.0
Pyrilamine Tannate 40.0
Phenylephrine Tannate 10.01
Starch, NF 65.0
Methylcellulose, USP 150  
Polygalacturoic Acid 32.0
Dibasic Calcium Phosphate, USP, Dihydrate 65.0
Povidone, USP 25.0
Talc, USP  5.4
FD&C Red #40 Aluminum Lake-40%  3.93
Magnesium Stearate, NF  4.0
Alcohol Specially Denatured 23A 190 Proof 1402 
115% excess added during manufacturing
2Not present in the finished tablet product

Suspensions of the compositions of the present invention are prepared in a conventional manner such that each 5 mL (one teaspoon) contains:

Carbetapentane Tannate 30 mg
Pyrilamine Tannate 30 mg
Phenylephrine Tannate 5 mg

The suspension formulations additionally contain benzoic acid, colorants, natural and artificial flavors, glycerin, kaolin, magnesium aluminum silicate, methylparaben, pectin, purified water, saccharin, sodium hydroxide and sucrose or sorbitol.

Example 2, which follows, is illustrative of a typical suspension formulation of the present invention prepared by conventional well known compounding techniques.

EXAMPLE 2 Carbetapentane Tannate, Pyrilamine Tannate and Phenylephrine Tannate Suspension

Ingredient Milligrams per 5 mL
Carbetapentane Tannate 30.0
Pyrilamine Tannate 30.01
Phenylephrine Tannate 5.02
Pectin, USP (Medium Viscosity) 50.0
Kaolin, USP (Colloidal Powder) 1000
Magnesium Aluminum Silicate, NF 35.0
Benzoic Acid, USP 10.0
Methylparaben, NF 2.5
Sucrose, NF 1000
Saccharin Sodium, USP 0.75
Glycerin, USP 225
Flavor Black Currant Imitation 0.91
Flavor Strawberry with Other Natural Flavors 2.28
Purple Shade R Dye 0.45
FD&C Red #3 Dye 0.8
FD&C Yellow #5 0.3
Sodium Hydroxide Solution-50% 0.7933
Purified Water, USP (Deionized) adjust to 5 mL
15% excess added during manufacturing
215% excess added during manufacturing
3The quantity of Sodium Hydroxide Solution may be varied depending on the pH of the Kaolin used in the batch. Tannic acid may also be used in lieu of sodium hydroxide solution for pH adjustment. Sodium Citrate, USP, Dihydrate and Citric Acid, USP, Anhydrous may also be included in the formula for pH adjustment.

For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.

The dosage administered will be dependent on the age, health and weight of the recipient, kinds of concurrent treatment, if any, frequency of treatment and effect desired.

It should be understood that the above examples are illustrative of the best mode only of the invention herein disclosed. Given the present disclosure, it is anticipated that numerous variations will occur to those skilled in the art. A latitude of modification, substitution and change is intended and in some instances, some features of the invention will be employed without a corresponding use of other features. Accordingly, it is intended that the spirit and scope of the invention disclosed herein should be limited only by the following claims.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US6287597Mar 12, 1999Sep 11, 2001Carter-Wallace, Inc.Antihistaminic/decongestant compositions
US6306904Jul 25, 2000Oct 23, 2001Carter-Wallace, Inc.Antihistaminic/antitussive compositions
JPS647786A * Title not available
Non-Patent Citations
Reference
1 *Luchem, DrugLaunch (Accession No.: 94: 41007) Jul. 29, 1991.*
2 *Weiler et al., Ann. Allergy, 64(1), 63-67 1990 (abstract).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6566396Nov 30, 2000May 20, 2003Medpointe Healthcare Inc.Carbetapentane tannate and chlorpheniramine tannate which are effective when administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis, and unproductive cough
US6586469Oct 26, 2001Jul 1, 2003Medpointe Healthcare Inc.Carbetapentane tannate and pyrilamine tannate are administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis, unproductive cough and upper respiratory tract conditions
US6790980Oct 2, 2002Sep 14, 2004First Horizon Pharmaceutical CorporationTannate compositions and methods of treatment
US7390922Mar 22, 2004Jun 24, 2008Kiel Laboratories, Inc.Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
US7456312Mar 22, 2004Nov 25, 2008Kiel Laborities, Inc.making gabapentin tannate to treat central nervous system disorders by reacting gabapentin and tannic acid; used in sustained release applications and to improve certain organoleptic properties such as taste
US7550628Mar 22, 2004Jun 23, 2009Kiel Laboratories, Inc.Process for preparing phenolic acid salts of gabapentin
US7786168Jun 13, 2008Aug 31, 2010Kiel Laboratories, Inc.Phenolic acid salts of gabapentin in solid dosage forms and methods of use
US7914828Oct 19, 2009Mar 29, 2011Levine Brian MCombination herbal product to benefit respiratory tract
US8361519Nov 16, 2011Jan 29, 2013Aadvantics Pharmaceuticals, Inc.Combination herbal product to benefit respiratory tract in people exposed to smoke
US8679553Dec 26, 2012Mar 25, 2014Aadvantics Pharmaceuticals, Inc.Combination herbal product to benefit the respiratory tract in people exposed to smoke
WO2005023236A1 *Jun 29, 2004Mar 17, 2005Jeffrey S KielPhenylephrine tannate, pyrilamine tannate, and dextromethorphan tannate salts in pharmaceutical compositions
Classifications
U.S. Classification514/352, 514/653, 514/530
International ClassificationA61K31/4402, A61K31/137, A61K31/216
Cooperative ClassificationA61K31/216, A61K31/4402, A61K31/137
European ClassificationA61K31/4402, A61K31/216, A61K31/137
Legal Events
DateCodeEventDescription
Feb 14, 2014REMIMaintenance fee reminder mailed
Dec 14, 2009FPAYFee payment
Year of fee payment: 8
Aug 25, 2008ASAssignment
Owner name: MEDA PHARMACEUTICALS INC., NEW JERSEY
Free format text: CHANGE OF NAME;ASSIGNOR:MEDPOINTE HEALTHCARE INC.;REEL/FRAME:021428/0945
Effective date: 20071212
Jun 6, 2006ASAssignment
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, MARYLAND
Free format text: SECURITY AGREEMENT;ASSIGNOR:MEDPOINTE HEALTHCARE INC.;REEL/FRAME:017730/0008
Effective date: 20060524
May 25, 2006ASAssignment
Owner name: MEDPOINTE HEALTHCARE INC., NEW JERSEY
Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:LEHMAN COMMERICAL PAPER INC.;REEL/FRAME:017675/0384
Effective date: 20060524
Dec 7, 2005FPAYFee payment
Year of fee payment: 4
Jul 12, 2005ASAssignment
Owner name: MEDPOINTE HEALTHCARE INC., NEW JERSEY
Free format text: CHANGE OF NAME;ASSIGNOR:CARTER-WALLACE, INC.;REEL/FRAME:016245/0386
Effective date: 20011001
Oct 24, 2001ASAssignment
Owner name: LEHMAN COMMERCIAL PAPER INC., NEW JERSEY
Free format text: SECURITY AGREEMENT;ASSIGNORS:MEDPOINT INC.;MCC ACQUISITION SUB CORPORATION;MCC MERGER SUB CORPORATION;REEL/FRAME:012530/0854
Effective date: 20010928
Owner name: LEHMAN COMMERCIAL PAPER INC. 101 HUDSON STREET, 31
Free format text: SECURITY AGREEMENT;ASSIGNORS:MEDPOINT INC. /AR;REEL/FRAME:012530/0854
Jan 26, 2001ASAssignment
Owner name: CARTER-WALLACE, INC., NEW YORK
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEFLEIN, RONALD;D ADDIO, ALEXANDER D.;REEL/FRAME:011853/0992
Effective date: 20010125
Owner name: CARTER-WALLACE, INC. 1345 AVENUE OF THE AMERICAS N
Owner name: CARTER-WALLACE, INC. 1345 AVENUE OF THE AMERICASNE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEFLEIN, RONALD /AR;REEL/FRAME:011853/0992